Alvotech Expands its Partnership with Advanz Pharma to Commercialize Three Additional Biosimilars in the EU

Shots:

• Alvotech has entered into an agreement with Advanz Pharma to expand their commercial partnership to include 3 more biosimilar candidates
• As per the deal, Advanz will register & commercialize biosimilars of Ilaris (canakinumab), Kesimpta (ofatumumab), & an undisclosed biologic in the EU, while Alvotech will handle development & commercial supply; partners will share revenues, with Alvotech receiving ~$180M in development & commercial milestones
• In 2023, Alvotech & Advanz Pharma partnered to commercialize biosimilars of Xolair (AVT23), Simponi, Entyvio, Eylea, Eylea HD, Dupixent, Taltz, & Tremfya across the EEA, UK, & Switzerland, with AVT23’s agreement also covering Canada, Australia, & New Zealand

Ref:  Globenewswire| Image:  Alvotech & Advanz Pharma| Press Release

Related News:- Teva and Alvotech’s Selarsdi (Biosimilar, Stelara) Receives the US FDA’s Interchangeability Designation

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com